Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to $160.4 million.

  • Cidara Therapeutics' Net Cash Flow fell 486.55% to -$216.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.6 million, marking a year-over-year increase of 119.27%. This contributed to the annual value of $160.4 million for FY2024, which is 5164.16% up from last year.
  • Cidara Therapeutics' Net Cash Flow amounted to $160.4 million in FY2024, which was up 5,164.16% from $3.0 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Net Cash Flow ranged from a high of $160.4 million in FY2024 and a low of -$29.5 million during FY2022.
  • Over the past 3 years, Cidara Therapeutics' median Net Cash Flow value was $3.0 million (recorded in 2023), while the average stood at $44.6 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Net Cash Flow slumped by 252.88% in 2022, and later spiked by 5,164.16% in 2024.
  • Cidara Therapeutics' Net Cash Flow (Yearly) stood at -$17.3 million in 2020, then skyrocketed by 211.58% to $19.3 million in 2021, then crashed by 252.88% to -$29.5 million in 2022, then skyrocketed by 110.31% to $3.0 million in 2023, then skyrocketed by 5,164.16% to $160.4 million in 2024.